Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Tumor Growth Blocked in Mice by Suppressing Antioxidants in Cancer Cells

By BiotechDaily International staff writers
Posted on 11 Dec 2013
Many cancers have adapted to deal with the high levels of immune system-produced free radicals, also referred to as reactive oxygen species, by overproducing antioxidant proteins. One of these proteins, superoxide dismutase 1 (SOD1), is overproduced in lung adenocarcinomas and has been implicated as a target for chemotherapy.

In the December 2, 2013, issue of the Journal of Clinical Investigation, Dr. Navdeep Chandel and colleagues from Northwestern University (Evanston, IL, USA) reported the effects of a SOD1 pharmacologic suppressor on non-small-cell lung cancer (NSCLC) cells. The inhibitor, called ATN-224, blocked the growth of human NSCLC cells in culture, and triggered their death. The researchers also discovered that ATN-224 inhibited other antioxidant proteins, which caused high levels of hydrogen peroxide inside the cells. Cancer cells’ capability to generate hydrogen peroxide was required for ATN-224-dependent effects, because hydrogen peroxide activated cell death pathways.

ATN-224, moreover, triggered cancer cell death and decreased tumor sizes in a mouse model of lung adenocarcinoma. ATN-224-dependent effects in lab mice were enhanced when the inhibitor was used in combination with another drug that activates programmed cell death.

These new findings indicate that antioxidant suppression may be a feasible chemotherapeutic strategy.

Related Links:

Northwestern University



Channels

Genomics/Proteomics

view channel
Image: The photomicrograph shows the head of a mouse embryo in which the pericytes are visible as blue dots along the blood vessel (Photo courtesy of the University of Gothenburg).

Genetically Engineered Mouse Model Reveals Key to Formation of the Blood-Brain Barrier

Use of a mouse model that had been genetically engineered to lack the gene that encodes the forkhead transcription factor Foxf2 has helped to explain how pericytes, cells that line the capillaries, form... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.